Securities code: 300871 securities abbreviation: Hvsen Biotechnology Co.Ltd(300871) Announcement No.: 2022-003 convertible bond Code: 123132 convertible bond abbreviation: Huisheng convertible bond
Hvsen Biotechnology Co.Ltd(300871)
Announcement on resolutions of the 19th meeting of the second board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
The 19th meeting of the second board of supervisors of Hvsen Biotechnology Co.Ltd(300871) (hereinafter referred to as "the company" or " Hvsen Biotechnology Co.Ltd(300871) ") was held on site in the company's conference room on January 21, 2022. The notice of the meeting was sent by e-mail and telephone on January 17, 2022. The meeting was presided over by Mr. Chen Peifeng, chairman of the board of supervisors of the company. There were 3 supervisors who should attend the meeting and 3 supervisors who actually attended the meeting. The convening, convening and voting procedures of this meeting comply with the relevant provisions of the company law of the people's Republic of China and the articles of association.
2、 Deliberation at the meeting of the board of supervisors
After careful deliberation and voting, the attending supervisors formed the following resolutions:
(I) the proposal on using raised funds to replace self raised funds invested in raised investment projects in advance and paid issuance expenses was deliberated and adopted
After deliberation, the board of supervisors agreed that the company would use the funds raised by issuing convertible corporate bonds to unspecified objects of RMB 142.2575 million to replace the self raised funds invested in the early stage. The matter complies with the relevant provisions of the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 - standardized operation of companies listed on the gem, the guidelines for supervision of listed companies No. 2 - regulatory requirements for the management and use of raised funds of listed companies (revised in 2022) and the articles of association, There is no change or disguised change in the investment direction of the raised funds and damage to the interests of shareholders.
For details, please refer to cninfo.com.cn, the gem information disclosure platform designated by the CSRC on January 22, 2022 Relevant announcements disclosed.
The voting result is: 3 affirmative votes; No negative votes; There were no abstentions. The motion was passed.
(II) the proposal on adjusting the amount and period of cash management using idle raised funds and self owned funds was deliberated and adopted
The board of supervisors of the company believes that the amount and period of idle raised funds and self owned funds for cash management are adjusted this time, Comply with relevant laws and regulations such as guidelines for the supervision of listed companies No. 2 - regulatory requirements for the management and use of raised funds by listed companies (revised in 2022), guidelines for the self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 - standardized operation of companies listed on GEM, and the company's raised funds management system, which is conducive to the rational use of idle funds, Improve capital use efficiency and increase investment income. This matter is carried out on the premise of ensuring the safety of the principal of the company's raised funds and normal production and operation, and will not affect the construction of the company's raised funds and the normal development of the company's main business. There is no change in the purpose of the raised funds in a disguised form, and there is no damage to the interests of the company and all shareholders, especially small and medium-sized shareholders. Therefore, the board of supervisors agreed to adjust the amount and period of idle raised funds and self owned funds for cash management. For details, please refer to cninfo.com.cn, the gem information disclosure platform designated by the CSRC on January 22, 2022 Relevant announcements disclosed.
The voting result is: 3 affirmative votes; No negative votes; There were no abstentions. The motion was passed.
(III) the proposal on adjusting the company's performance evaluation indicators of the company's restricted stock incentive plan in 2021 was deliberated and adopted
The board of supervisors of the company believes that the adjustment of the performance evaluation indicators of the company in 2022-2023 of the restricted stock incentive plan in 2021 can further stimulate the enthusiasm of the company's senior managers and core backbone employees, which is conducive to the long-term sustainable development of the company. There is no damage to the interests of the company and all shareholders, especially small and medium-sized shareholders, and the voting procedures and processes are legal and compliant, Comply with relevant laws and regulations.
For details, please refer to cninfo.com.cn, the gem information disclosure platform designated by the CSRC on January 22, 2022 Relevant announcements disclosed.
This proposal needs to be submitted to the general meeting of shareholders for deliberation and approval by more than two-thirds (including) of the total number of effective voting shares held by non affiliated shareholders attending the general meeting of shareholders.
The voting result is: 3 affirmative votes; No negative votes; There were no abstentions. The motion was passed.
3、 Documents for future reference
Resolution of the 19th meeting of the second board of supervisors.
It is hereby announced.
Hvsen Biotechnology Co.Ltd(300871) board of supervisors January 22, 2022
